Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-04-05
2005-04-05
Navarro, Mark (Department: 1645)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069200, C435S069300, C435S069500, C514S04400A
Reexamination Certificate
active
06875584
ABSTRACT:
Polypeptide and polynucleotide vaccines effective to treat or prevent infection of a mammal, such as a dog, a cat, or a human, by a protozoan. Methods of treatment and prevention are also provided, including therapeutic administration of the vaccine to an infected mammal to prevent progression of infection to a chronic debilitating disease state. Preferred embodiments of the polynucleotide vaccine contain nucleotide coding regions that encode polypeptides that are surface-associated or secreted byT. cruzi. Optionally the efficacy of the polynucleotide vaccine is increased by inclusion of a nucleotide coding region encoding a cytokine. Preferred embodiments of the polypeptide vaccine include immunogenic peptides that contain membrane transducing sequences that allow the polypeptides to translocate across a mammalian cell membrane.
REFERENCES:
patent: 5304371 (1994-04-01), Reed
patent: 5646114 (1997-07-01), Lambert et al.
Platin et al Vaccines W.P. Sanders Co Philadelphia p. 571, 1988.*
Denkers et al. (Clin Microbiol Rev 1998 vol. 11 pp. 569-588).*
Higuchi et al., “The Role of Active Myocarditis in the Development of Heart Failure in Chronic Chagas' Disease: A Study Based on Endomyocardial Biopsies,”Clin. Cardiol. 10(11):665-670 (1987).
Low et al., “Identification of the 83-kDa Amastigote Surface Protein of Trypanosoma cruzi as a Member of the Sialidase Family and a Target of CTL Responses,” Abstract and Poster, Joint Meeting of the Amer. Soc. Tropical Med. Hyg., Amer. Soc. Parasitologists, Baltimore, MD 6 pages (1996).
Santos et al., “The Identification and Molecular Characterization of a Trypanosoma cruzi Amastnigote Surface Protein, Asp-1, a Member of the Trans-Sialidase Gene Superfamily,” Abstract and Poster, Joint Meeting of the Amer. Soc. Biochemistry and Molecular Biology, Amer. Soc. Investigative Pathology, and Amer. Assoc. Immunologists, Jun. 1-6, New Orleans, LA,FASEB J. 10(6):A1083 9 pages (1996).
World Health Organization, “Special programme for research and training in tropical diseases, Sixth Programme Report, Chapter Six: Chagas' Disease,” TDR/PR-6/83.6—CHA, UNDP/World BankWHO (1983).
World Health Organization, “Special programme for research and training in tropical diseases; Meeting on the development of trypanocidal compounds for the sterilization of blood,” Geneva, Dec. 13-14, TDR/CHA/BS/84.3, UNDP/World Bank/WHO (1984).
Armah et al., “S-Myristoylation of a Glycosylphosphatidylinositol-specific Phospholipase C inTrypanosoma brucei,”J. Biol. Chem., 274(9):5931-5938 (Feb. 26, 1999).
Abrahamson, “Cytokines in innate and acquired immunity toTrypanosoma cruziinfection,”Braz. J. Med. Biol. Res., 31(1):117-121 (Jan. 1998).
Alberti et al., “Specific cellular and humoral immune response in Balb/c mice immunised with an expression genomic library ofTrypanosoma cruzi,”Vaccine, 16(6):608-612 (Apr. 1998).
Al Qahtani et al., “A 5' untranslated region which directs accurate and robust translation by prokaryotic and mammalian ribosomes,”Nuc. Acids Res., 24(6):1173-1174 (1996).
Andrerws et al., “Presence of antibodies to the major surface glycoprotein ofTrypanosoma cruziamastigotes in sera from chagasic patients,”Am. J. Trop. Med. Hyg., 40(1):46-49 (1989).
Andrews, “The Acid-Active Hemolysin ofTrypanosoma cruzi,”Exp. Parasitol., 71:241-244 (1990).
Barry et al., “Protection against mycoplasma infection using expression-library immunization,”Nature, 377(6550):632-635 (1995).
Barry et al., “Biological features of genetic immunization,”Vaccine, 15(8):788-791 (1997).
Basombrio, “Trypanosoma cruzi: Partial Prevention of the Natural Infection of Guinea Pigs with a Killed Parasite Vaccine,”Exp. Parasitol., 71:1-8 (1990).
Bharadwaj et al., “Induction of Protective Immune Responses by Immunization with Linear Multiepitope Peptides Based on Conserved Sequences fromPlasmodium falciparumAntigens,”Infect. Immun., 66(7):3232-3241 (Jul. 1998).
Biebinger et al., “A Plasmid Shuttle Vector Bearing an rRNA Promoter is Extrachromosomally Maintained inCrithidia fasciculata,”Exp. Parasitol., 83(2):252-258 (1996).
Bliss et al., “IL-12, as an Adjuvant, Promotes a T Helper 1 Cell, but Does Not Suppress a T Helper 2 Cell Recall Response,”J. Immunol., 156:(3):887-894 (1996).
Brener, “Why Vaccines do not work in Chagas Disease,”Parasitol. Today, 2(7):196-197 (1986).
Carpenter et al., “Linearized free maxicircle DNA inCrithidia fasciculatais a product of topidomerase II-mediated cleavage,”Mol. Biochem. Parasitol., 76:115-123 (1996).
Chow et al., “Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes,”J. Immunol., 160(3):1320-1329 (Feb. 1, 1998).
Clayton et al., “Protein Trafficking in Kinetoplastid Protozoa,”Microbiol. Rev., 59(3):325-344 (1995).
Coburn et al., “Stable DNA transfection of a wide range of trypanosomatids,”Mol. Biochem. Parasitol., 46:169-179 (1991).
Conry et al., “Polynucleotide-Mediated Immunization Therapy of Cancer,”Seminars Oncol., 23(1):135-147 (1996).
Costa et al., “Immunizations with a plasmid DNA containing the gene oftrans-sialidase reducesTrypanosoma cruziinfection in mice,”Vaccine, 16(8):768-774 (May 1998).
Cross et al., “The SurfaceTrans-Sialidase Family ofTrypansoma cruzi,”Ann. Rev. Microbiol., 47:385-411 (1993).
DeRisi et al., “Use of a CDNA microarray to analyse gene expression patterns in human cancer,”Nature Genet., 14(4):457-460 (1996).
DeRisi et al., “Exploring the Metabolic and Genetic Control of Gene Expresion on a Genomic Scale,”Science, 278(5338):680-686 (1997).
Donnelly et al., “DNA Vaccines,”Ann. Rev. Immunol., 15:617-648 (1997).
Endresz et al., “Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specifc cytotoxic T lymphocyte responses by naked DNA immunication,”Vaccine, 17(1):50-58 (Jan. 1999).
Englund, “The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors,”Annu. Rev. Biochem., 62:121-138 (1993).
Freedman et al., “Two more independent selectable markers for stable transfection ofLeishmania,” Mol. Biochem. Parasitol., 62:37-44 (1993).
Fontt et al., “Relationship between granulocyte macrophage-colony stimulating factor, tumour necrosis factor-αandTrypanosama cruziinfection of murine macrophages,”Parasite Immunol., 17(3):135-141 (1995).
Fontt et al., “Granulocyte-Macrophage Colony-Stimulating Factor: Involvement in Control ofTrypanosoma cruziInfection in Mice,”Infect. Immun., 64(8):3429-3434 (1996).
Fontt et al., “Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Tumor Necrosis Factor Alpha onTrypanosoma cruziTrypomastigotes,”Infect. Immun., 66(6):2722-2727 (Jun. 1998).
Fouts et al., “Nucleotide sequence and transcription of a tryomastigote surface antigen gene ofTrypanosoma cruzi,”Mol. Biochem. Parasitol., 46:189-200 (1991).
Fouts et al., “Trypanosoma cruzitrypomastigote surface glycoprotein (TSA-1) mRNA, GenBank Accession No. M58466,” (1993).
Garg et al., “Proteins with Glycosylphosphatidylinositol (GPI) Signal Sequences Have Divergent Fates during a GPI Deficiency,”J. Biol. Chem., 272(19):12482-12491 (1997).
Garg et al., “Delivery byTrypanosoma cruziof Proteins into the MHC Class I Antigen Processing and Presentation Pathway,”J. Immunol., 158:3293-3302 (1997).
Garg et al., “Elicitation of protective immunity toTrypanosoma cruziusing DNA vaccines,” Proceedings of the 10thInternational Congress of Immunology, New Delhi, India, Monduzzi, Bologna pp. 1421-1426 (Nov. 1-6, 1998).
Geissler et al.,
Garg Nisha
Tarleton Rick L.
Mueting Raasch & Gebhardt, P.A.
Navarro Mark
University of Georgia Research Foundation Inc.
LandOfFree
Prophylactic and therapeutic immunization against protozoan... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prophylactic and therapeutic immunization against protozoan..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prophylactic and therapeutic immunization against protozoan... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3431471